Pancreatic Cancer Patients Have Elevated Fructose Levels New Test May Help in Understanding the Health Effects of High Fructose Intake

Key points
- Patients with pancreatic cancer have higher-than-normal blood levels of the refined sugar fructose, according to a recent study in the journal Pancreas (www.pancreasjournal.com), official journal of the American Pancreatic Association and the Japan Pancreas Society.
- The researchers developed and evaluated a new test to measure the level of fructose in blood samples.
- The same test was used to measure fasting fructose levels in patients with pancreatic cancer.
- Pancreas (www.pancreasjournal.com) provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states.
Patients with pancreatic cancer have higher-than-normal blood levels of the refined sugar fructose, according to a recent study in the journal Pancreas (www.pancreasjournal.com), official journal of the American Pancreatic Association and the Japan Pancreas Society. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
The study also lends new insights into the way the body handles fructose, compared to other sugars. The results may provide important clues to understanding the health effects of high fructose intake—including a recent study linking consumption of soft drinks to pancreatic cancer risk. The study was led by Anthony P. Heaney, M.D., of David Geffen School of Medicine at UCLA.
Body's Handling of Fructose Is 'Underdeveloped,' Test Suggests
The researchers developed and evaluated a new test to measure the level of fructose in blood samples. Fructose is a natural sugar that, in highly refined and concentrated forms, is widely used in commercially produced foods and beverages, including soft drinks.
After confirming the precision of the new test, the researchers used it to measure fructose levels in healthy volunteers. After an overnight fast, the volunteers drank two cans of sugared soda—which contains a high dose of fructose, in addition to glucose. After drinking the soda, the volunteers' serum fructose level rose dramatically—more than eight times higher within 30 minutes. Fructose level decreased gradually, remaining elevated for longer than two hours.
In contrast, the volunteers' serum glucose levels did not rise as sharply and returned to normal within one hour. The difference suggests that the body is unable to metabolize such a large dose of fructose as rapidly as glucose. "[T]he human capacity to deal with large fructose loads is underdeveloped in comparison to tight physiological glucose control," Dr. Heaney and coauthors write.
In Pancreatic Cancer Patients, Fructose Levels Are Higher
The same test was used to measure fasting fructose levels in patients with pancreatic cancer. Their fructose level was more than twice as high as in healthy volunteers. (The pancreatic cancer patients did not perform the soda/high-fructose test.)
This result takes on special importance in light of preliminary studies linking fructose intake to obesity, diabetes, and other health problems—including pancreatic cancer. Most recently, a study reported that people who regularly drink soda may be more likely to develop pancreatic cancer. In that study, published in the February issue of Cancer Epidemiology Biomarkers & Prevention, people who drank two or more sodas per week had an 87 percent increase in pancreatic cancer risk.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsTiny particles in blood useful for early diagnosis of pancreatic cancer
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable…
26 June 2015
NewsA Boost May Improve Pancreatic Cancer Resection Rate
A "vessel boost" (VB) dose of radiation could increase the likelihood that patients with borderline resectable and locally advanced pancreatic cancer will be able to undergo surgical resection, thus increasing survival…
19 June 2015
NewsGenomic testing can help identify patients at heightened risk for esophageal cancer
Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus. Although periodic surveillance for cancer is…







